Codexis, Inc. (NASDAQ:CDXS) SVP James Lalonde sold 17,915 shares of Codexis stock in a transaction on Tuesday, February 12th. The stock was sold at an average price of $21.63, for a total value of $387,501.45. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ CDXS traded down $0.70 during mid-day trading on Wednesday, reaching $21.45. The company’s stock had a trading volume of 751,100 shares, compared to its average volume of 479,737. Codexis, Inc. has a 52 week low of $8.25 and a 52 week high of $23.05. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -42.90 and a beta of -0.37.
Get Codexis alerts:
Several research analysts have commented on the company. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 5th. ValuEngine lowered Codexis from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 4th. Zacks Investment Research lowered Codexis from a “buy” rating to a “hold” rating in a research report on Friday, January 18th. First Analysis upgraded Codexis from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $19.00 in a research note on Thursday, January 17th. Finally, Jefferies Financial Group increased their price target on Codexis from $4.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, January 15th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Codexis has an average rating of “Buy” and a consensus target price of $19.50.
Several hedge funds and other institutional investors have recently modified their holdings of CDXS. Quantamental Technologies LLC bought a new position in Codexis in the fourth quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Codexis by 152.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 1,711 shares during the last quarter. United Services Automobile Association purchased a new position in shares of Codexis during the 3rd quarter valued at about $195,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Codexis in the 4th quarter valued at about $217,000. Finally, Financial Architects Inc increased its stake in shares of Codexis by 36.3% in the 3rd quarter. Financial Architects Inc now owns 15,130 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 4,027 shares in the last quarter. Hedge funds and other institutional investors own 80.21% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Codexis, Inc. (CDXS) SVP James Lalonde Sells 17,915 Shares” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4149599/codexis-inc-cdxs-svp-james-lalonde-sells-17915-shares.html.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Story: How to find the components of the quick ratio